Publisher
Norwegian Medical Association
Reference8 articles.
1. Hetland ML, Haavardsholm EA, Rudin A et al. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. BMJ 2020; 371: m4328. [PubMed][CrossRef]
2. Smolen JS, Landewé RBM, Bergstra SA et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 2023; 82: 3–18. [PubMed][CrossRef]
3. Solomon DH, Kremer JM, Fisher M et al. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum 2014; 43: 489–97. [PubMed][CrossRef]
4. Boleto G, Kanagaratnam L, Dramé M et al. Safety of combination therapy with two bDMARDs in patients with rheumatoid arthritis: A systematic review and meta-analysis. Semin Arthritis Rheum 2019; 49: 35–42. [PubMed][CrossRef]
5. Alayo QA, Fenster M, Altayar O et al. Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease. Crohns Colitis 360 2022; 4: otac002. [PubMed][CrossRef]